HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
We demonstrated that the prognosis of breast cancer patients who received adjuvant immunochemotherapy with Krestin (PSK) showed a tendency to be better than that of breast cancer patients receiving chemotherapy only. We retrospectively investigated the usefulness of HLA typing for selecting patients to receive adjuvant immuno-chemotherapy with PSK. One hundred and thirty-four patients with operable breast cancer were typed as HLA-A, -B, -C by a lymphocytotoxicity test. Patients without vascular invasion had no adjuvant therapy (NA group). Patients with vascular invasion in the tumor and/or in the metastatic lymph node were randomized into two groups. In group 1 (FEMP only), a combination chemotherapy of 100 mg of 5-fluorouracil (F), 50 mg of cyclophosphamide (E), 2 mg of mitomycin C (M), and 5 mg of predonisolone (P) was orally administered daily for 28 days (one course). In group 2 (FEMP+PSK), FEMP and 3.0 g of PSK were orally administered for 28 days (one course). Two courses a year of these agents were given for five years in both groups. Each group (NA, FEMP, FEMP+PSK) was stratified by the presence of HLA B40 type (B40(+)) or not (B40(-)). Five- and 10-year disease-free survival (DFS) rates (93%, 80%, respectively) of patients with B40(+) seemed to be better than those (83% and 51%) of patients with B40(-). In the NA group, 5- and 10-year DFS were 100% and 71% in patients with B40(+), 92% and 76% in those with B40(-), respectively. In the FEMP group (chemotherapy only), 5- and 10-year DFS of patients with B40(+) were both 84%. These were not statistically significant compared with those (82% and 33%) of patients with B40(-). On the other hand, in the FEMP+PSK group, 5- and 10-year DFS of patients with B40(+) were both 100%, and those of patients with B40(-) were 76% and 55%, respectively. DFS of patients with B40(+) was significantly better than that of patients with B40(-). It is concluded that HLA typing may be a predictive index in determining the use of immunochemotherapy combined with PSK for patients with operable breast cancer.
Yokoe
T
T
Department of Emergency and Critical Care Medicine, Gunma University School of Medicine, Japan.
Iino
Y
Y
Takei
H
H
Horiguchi
J
J
Koibuchi
Y
Y
Maemura
M
M
Ohwada
S
S
Morishita
Y
Y
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006680:HLA Antigens / Q000032:analysis*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008875:Middle Aged; D011379:Prognosis; D011509:Proteoglycans / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis
D000276:Adjuvants, Immunologic; D006680:HLA Antigens; D011509:Proteoglycans; C010770:polysaccharide-K